Agios Pharmaceuticals (NASDAQ:AGIO) Sets New 52-Week Low – Here’s What Happened

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $23.00 and last traded at $23.4660, with a volume of 2343587 shares changing hands. The stock had previously closed at $45.49.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Zacks Research raised Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 4th. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. HC Wainwright restated a “buy” rating and set a $56.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, September 4th. Scotiabank lowered their price objective on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a research note on Monday, July 28th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Thursday, November 13th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $57.25.

Agios Pharmaceuticals Stock Down 45.7%

The firm’s 50-day moving average price is $40.64 and its two-hundred day moving average price is $37.01. The firm has a market capitalization of $1.44 billion, a PE ratio of -3.45 and a beta of 0.89.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm had revenue of $12.90 million during the quarter, compared to analyst estimates of $10.49 million. During the same quarter last year, the business posted $16.22 EPS. The company’s revenue was up 43.3% on a year-over-year basis. Equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 3,302 shares of Agios Pharmaceuticals stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $43.92, for a total transaction of $145,023.84. Following the transaction, the insider owned 61,727 shares of the company’s stock, valued at $2,711,049.84. The trade was a 5.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Cecilia Jones sold 3,651 shares of the stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $36.77, for a total transaction of $134,247.27. Following the completion of the sale, the chief financial officer directly owned 33,870 shares of the company’s stock, valued at $1,245,399.90. This trade represents a 9.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 16,099 shares of company stock worth $620,092. 4.93% of the stock is currently owned by company insiders.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals during the 1st quarter valued at $40,000. First Horizon Corp acquired a new stake in shares of Agios Pharmaceuticals in the third quarter worth $45,000. CWM LLC boosted its holdings in shares of Agios Pharmaceuticals by 150.2% during the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 996 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Agios Pharmaceuticals by 16.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 320 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Agios Pharmaceuticals in the 3rd quarter worth $79,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.